Psilocybin Dosing Guidelines
There are no established clinical dosing guidelines for psilocybin in routine medical practice, as it remains an investigational agent without FDA approval for therapeutic use.
Current Research-Based Dosing Framework
Based on the most recent and highest-quality evidence from clinical trials, the following dosing patterns have emerged:
Standard Therapeutic Doses
For depression and anxiety in palliative care or psychiatric conditions, the optimal dose appears to be 25-30 mg as a fixed oral dose 1, 2, 3. This represents the most robust finding across multiple studies:
- 25 mg fixed dose: Produces clinically meaningful effects with good tolerability 1, 4
- 30-35 mg/70 kg weight-adjusted: Associated with optimal antidepressant effects in meta-analysis 2
- Fixed dosing is preferred over weight-adjusted dosing: Body weight does not significantly affect subjective effects or outcomes across a wide range (49-113 kg) 1
Pharmacokinetic Profile
The practical timeline for a single therapeutic session 3:
- Peak plasma levels: Occur at approximately 2 hours post-administration
- Duration of subjective effects: 5-6 hours on average
- Elimination half-life: 1.4-1.8 hours
- Complete clearance: Within 24 hours
Microdosing Regimens
For sub-hallucinogenic effects, the emerging pattern is 5:
- Dose range: 1/10th to 1/20th of recreational doses (approximately 1-3 mg)
- Schedule: Every 3 days (not daily)
- Important caveat: This remains highly experimental with minimal rigorous evidence
Administration Protocol
Single-session approach is standard in clinical trials 6:
- Administer as a single oral dose in a controlled, supervised setting
- Continuous monitoring for 6-8 hours post-administration
- 24-hour observation period recommended
- Preparatory counseling sessions (6-8 hours) before first dose 4
Critical Safety Considerations
Contraindications to consider 6:
- Active psychosis or schizophrenia spectrum disorders
- Severe cardiovascular disease (psilocin causes transient increases in blood pressure and heart rate)
- Concurrent use of serotonergic medications (theoretical serotonin syndrome risk)
- Uncontrolled hypertension
Common transient adverse effects 4, 3:
- Nausea and vomiting (most common)
- Temporary blood pressure and heart rate elevation
- Anxiety during acute effects
- All effects resolve within 24 hours
Important Clinical Caveats
This is NOT standard medical practice: Psilocybin remains a Schedule I controlled substance in most jurisdictions. The evidence presented reflects research protocols, not approved clinical guidelines. Any therapeutic use must occur within approved research settings or jurisdictions where legal frameworks permit such treatment 6.
The "set and setting" matters profoundly: Unlike conventional medications, psilocybin's therapeutic effects are highly dependent on psychological preparation, therapeutic support during the experience, and integration afterward. The drug alone, without this structured framework, does not replicate research outcomes 6.
Renal impairment requires no adjustment: Less than 2% of psilocin is renally excreted, suggesting no dose reduction needed for mild-moderate renal impairment 4.